Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2021-07-07 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as the '5% Rule' report). It details the shareholding status, changes in ownership, and special relationships of the reporting entity (Gem & Company) and its related parties regarding the issuer (GemVax & KAEL). This falls under the category of Major Shareholding Notification.
2021-07-07 Korean
[기재정정]분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'GemVax & KAEL' (젬백스&카엘) covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial information, corporate governance details, share capital changes, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Although it mentions a 'correction' (정정신고), the core content is the quarterly financial report itself. 9M 2020
2021-07-07 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the company GemVax & KAEL, covering the fiscal year 2020. It includes detailed sections on company overview, history, capital changes, and financial information. This is the Korean equivalent of an Annual Report (10-K). Although it mentions a 'correction report' (정정신고) at the beginning, the document itself contains the full substance of the annual filing. FY 2020
2021-07-07 Korean
[기재정정]분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company GemVax & KAEL, covering the period from January 1, 2021, to March 31, 2021. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-07-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service (국민연금공단) regarding their stake in GemVax & Kael (주)젬백스&카엘. This type of filing is a standard regulatory requirement in South Korea when an entity's shareholding crosses specific thresholds (typically 5%). It details the number of shares held, changes in ownership, and the purpose of the holding. This falls under the 'Major Shareholding Notification' category.
2021-07-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives and major shareholders to report changes in their shareholdings in a listed company. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers insider trades and changes in ownership by company directors and executives.
2021-06-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.